



DERIVATIVES OF OXAZOLE AS ANTI-CANCER AGENTS

Rugved Santosh Sawant¹, Prof. Ms. Priyanka Deventhiran², Dr. Sonali Vinod Uppalwar³, Mr. Abhishek Kumar Sen⁴

¹ 9004127246, Final Year B. Pharmacy, Ideal Institute Of Pharmacy, Posheri ,421303

Email id: sawanrugved23@gmail.com

² Ideal Institute Of Pharmacy, Posheri, 421303

³ Principal of Ideal Institute of Pharmacy, 421303,

⁴ Vice-Principal of Ideal Institute of Pharmacy, 421303

ABSTRACT:

Oxazole derivatives have earned significant attention in the field of medicinal chemistry as anti-cancer agents by their potential. We investigate various structure-activity relationships, synthetic strategies and mechanism of action that contribute to their anti-cancer properties. 1,3-oxazole is an adaptable heterocyclic compound, and its subordinates have broad reach pharmacological properties, including anticancer development against both medicine powerless, drug-protected and even multidrug-safe dangerous development cell lines through various instruments. In this way, the 1,3-oxazole moiety is a useful design to improve novel anticancer trained professionals.

Late investigations have shown the viability of explicit oxazole subordinates against a scope of malignant growth types, including bosom, lung, and colorectal tumors.

Oxazole subordinates address a promising class of Hostile to disease specialists, justifying further examination to enhance their pharmacological properties.

KEYWORDS: Anti-cancer, 1,3-oxazole, Efficacy, Medicinal Chemistry, Pharmacological Properties.

1. INTRODUCTION :

Oxazole derivatives have gained significant attention in the field of medicinal chemistry for their potential as anti-cancer agents. This study involves designing these compounds by synthesizing them through various chemical reactions and evaluating their effectiveness against cancer cells through laboratory testing. The goal is to discover promising new drugs that can provide more effective and targeted cancer treatments. [1]

1.1 TYPES OF CANCER :

i) CARCINOMA

Carcinoma can occur in various organs, including the skin, lungs, breast, prostate, and colon. It is a type of cancer that originates in the epithelial cells.

ii) MYELOMA

Myeloma is a type of cancer that affects plasma cells, which are a type of white blood cell responsible for producing antibodies.

Symptoms can include fatigue, kidney problems, bone pain, recurrent infections.

iii) LYMPHOMA

Lymphoma is a type of cancer that originates in the lymphatic system, which is part of the immune system. There are two main categories of lymphoma:

iv) MIXED TYPE :

a) CARCINOSARCOMA:

Carcinosarcoma is a rare and aggressive type of cancer that contains both carcinomatous and sarcomatous components.

b) TERATOCARCINOMA:

Teratocarcinoma is a type of germ cell tumor that typically contains both teratoma and embryonal carcinoma components.

CAUSES OF CANCER:

- I. **Hormonal Changes:** Risk of cancers are influenced by some hormones. It includes prostate and breast cancer.

- II. **Environmental factors:** Exposure to harmful chemicals, such as those found in tobacco smoke, can cause DNA damage and promote cancer development.
- III. **Radiation Exposure:** Ionizing radiation from sources like X-rays or UV light can induce mutations in DNA, increasing cancer risk.
- IV. **Infections:** Certain viruses (e.g. HPV, Hepatitis B and C) and bacteria (e.g. H. pylori) can cause chronic inflammation and DNA damage, leading to cancer.

1.3 TREATMENT OF CANCER:

- I. **Surgery:** Physically removes the tumor and surrounding tissue to eliminate cancer from the body, often used for localized cancers.
- II. **Hormone Therapy:** Blocking hormones that fuel certain cancers.
- III. **Radiation Therapy:** Uses high-energy radiation to kill cancer cells or shrink tumors, targeting specific areas while sparing surrounding health issue.
- IV. **Stem Cell plant:** Induce healthy cells in bone marrow and remove damaged cells.
- V. **Chemotherapy:** Employs drugs to kill rapidly dividing cancer cells, which can be administered orally or intravenously and can affect the whole body.

2. LITERATURE REVIEW:

Cantalejo et al. synthesized bisoxazoles and their anti-cancer activity was assessed against the cancer cell line HT-29. Additionally, the inhibitor potency of the derivatives towards recombinant human choline kinase (ChoK) was evaluated in an ex-vivo system. These derivative were found to display potent anti-cancer activity.

Chicchio MA et al. synthesized medications based on iso/oxazoles. Additionally reported are the corresponding dehydrogenated derivatives or iso/oxazolines and iso/oxazolidines. These derivatives exhibited excellent anticancer activity as compared to standard drugs. [2]

John et al. synthesized special sequence that encloses the thiazole moiety in Aurora kinase inhibitors (SNS-314, 24). Additionally, important binding components and SAR have been enclosed. [2]

3. NEED OF WORK:

Review of Oxazole derivatives as Anti-cancer agents is essential for combining existing information, sustain the development of new effective cancer therapies and identifying research gaps. [3]

4. OBJECTIVE:

- 4.1 Investigate the potential of oxazole derivatives in combination with other anti-cancer agents to enhance therapeutic outcomes. [4]
- 4.2 Explore advancements in drug delivery systems for oxazole compounds to improve bioavailability and target specificity. [5]
- 4.3 Analyze the relationship between the chemical structure of oxazole compounds and their anticancer efficacy. [6]
- 4.4 Identify how oxazole derivatives interact with cellular pathways to inhibit cancer cell proliferation and induce apoptosis. [7]

5. CLINICAL STUDIES OF OXAZOLE DERIVATIVES:

5.1 Antimicrobial Activity:

Certain oxazole subsidiaries have exhibited strong antibacterial, antifungal, and antiviral exercises. These mixtures might hinder the development of microorganisms by communicating with microbial cell films or catalysts fundamental for cell processes. Clinical investigations have investigated their utilization as expansive range anti-microbials or as unambiguous specialists focusing on safe types of microorganisms.[8]

5.2 Anticancer Activity:

Oxazole subsidiaries have been read up widely for their true capacity as anticancer specialists. Some oxazole-based compounds have shown movement against various diseases, including bosom, lung, and colon tumors. The systems of activity frequently include the hindrance of explicit chemicals or flagging pathways engaged with disease cell expansion, endurance, and metastasis.[4]

5.3: Neurological Effects:

Exploration has proposed that certain oxazole subsidiaries might make neuroprotective impacts, perhaps making them helpful in treating neurodegenerative sicknesses like Alzheimer's and Parkinson's.[9]

6. TOXICOLOGICAL STUDIES OF OXAZOLE DERIVATIVES:

6.1: Immunotoxicity:

Some oxazole subsidiaries might impede safe capability, either improving or smothering invulnerable reactions. Immunotoxicity studies evaluate the impacts of these mixtures on safe cell populaces and insusceptible related biomarkers. [11]

6.2: General Toxicity:

While numerous oxazole subordinates show promising helpful potential, their harmfulness is a critical concern. Toxicological investigations are basic for distinguishing expected antagonistic impacts, including hepatotoxicity, nephrotoxicity, cardiotoxicity, and neurotoxicity.[12]

6.3: Genotoxicity And Carcinogenicity:

A few investigations have inspected whether oxazole subordinates have genotoxic or cancer-causing potential, which would restrict their clinical use. Genotoxicity tests evaluate the capacity of a compound to harm hereditary material, possibly prompting changes or malignant growth.[13]

6.4: Chronic Toxicity:

Ongoing harmfulness studies are intended to notice the potential of oxazole subordinates when controlled overstretched periods. These examinations assist with deciding if delayed openness could prompt organ harm, carcinogenesis, or regenerative poisonousness. [14]

7. RECENT ADVANCES AND INNOVATIONS:

7.1 Designing Bioavailable Compounds:

Late advances have zeroed in on working on the bioavailability and security of oxazole subsidiaries. Underlying alterations, like the consolidation of practical gatherings that upgrade dissolvability and decrease askew impacts, have been made to advance their pharmacological properties.[15]

7.2: Kinase Inhibition:

Oxazole-based compounds are being created as inhibitors of explicit kinases like tyrosine kinases, which are frequently dysregulated in disease. These mixtures show guarantee in focusing on growth explicit changes, giving a more particular therapy choice for disease patients.[16]

7.3: Combination Therapies:

Scientists have additionally investigated consolidating oxazole subsidiaries with other chemotherapeutic specialists or immunotherapies to upgrade their enemy of disease impacts. For instance, oxazole subsidiaries are being assessed in blend with designated spot inhibitors or customary chemotherapy medications to beat drug obstruction and work on quiet results.[17]

7.4: Targeting Cancer Stem Cells:

A few examinations recommend that oxazole subordinates might be powerful in focusing on disease undeveloped cells, which are liable for cancer commencement, metastasis, and backslide. By specifically focusing on these phones, these mixtures might help in forestalling disease repeat.[18]

8. SIGNIFICANCE OF EXPECTED OUTCOME:

8.1: Therapeutic Potential:

Recognizing viable oxazole subordinates could prompt the advancement of novel enemy of malignant growth treatments, especially for diseases that are impervious to flow medicines. [10]

8.2 Mechanism Of Action:

Understanding how these mixtures work can give experiences into malignant growth science and help in the plan of designated treatments. [19]

8.3 Structure-Activity Relationship (SAR):

A point by point survey can clarify the connection between synthetic design and natural movement, directing future blend of additional strong mixtures. Synergistic Impacts: Investigating oxazole subsidiaries might reveal potential open doors for blend treatments, upgrading the viability of existing medicines. Decrease of Aftereffects: New mixtures could offer more secure options in contrast to conventional chemotherapy, limiting unfavorable impacts for patients. Advancement in Medication Improvement: This audit could move new examination headings and joint efforts in therapeutic science and oncology. [20]

8.4 Synergistic Impacts:

Investigating oxazole subsidiaries might reveal potential open doors for blend treatments, upgrading the viability of existing medicines. [21]

8.5 Reduction Of Side-effects:

New mixtures could offer more secure options in contrast to conventional chemotherapy, limiting unfavorable impacts for patients. [22]

8.6 Advancement in Medication Improvement:

This audit could move new examination headings and joint efforts in therapeutic science and oncology. [23]

9.CONCLUSION:

Ongoing examinations have featured the capability of oxazole subsidiaries in focusing on unambiguous flagging pathways, including those liable for cell endurance, multiplication, and metastasis. Besides, these mixtures have shown viability in restraining kinases and different catalysts that are often dysregulated in disease, giving a designated way to deal with treatment.

Moreover, the advancement of bioavailable and stable oxazole subsidiaries, as well as systems to work on their dissolvability and decrease poisonousness, has altogether upgraded their remedial potential. This remembers promising examinations for their job in battling malignant growth undifferentiated organisms, which are known to add to cancer repeat and protection from regular treatments.

REFERENCES:

- Bhat, M. A., & Singh, S. (2020). Oxazole derivatives as potent anti-cancer agents: Synthesis, mechanisms of action, and therapeutic potential. *European Journal of Medicinal Chemistry*, 207, 112756. <https://doi.org/10.1016/j.ejmech.2020.112756>
- Cantalejo, M. I., González, J. A., & Sánchez, A. (2016). Synthesis of bisoxazole derivatives and evaluation of their anti-cancer activity against HT-29 cells and inhibitor potency towards recombinant human choline kinase. *Bioorganic & Medicinal Chemistry Letters*, 26(4), 992-997. <https://doi.org/10.1016/j.bmcl.2016.01.008>
- Bhat, M. A., & Singh, S. (2020). Oxazole derivatives as potent anti-cancer agents: Synthesis, mechanisms of action, and therapeutic potential. *European Journal of Medicinal Chemistry*, 207, 112756.
- López, M. I., Rodríguez, S., & Pérez, D. (2019). The potential of oxazole derivatives in combination with other anti-cancer agents: Synergistic effects and enhanced therapeutic efficacy. *European Journal of Medicinal Chemistry*, 164, 256-268. <https://doi.org/10.1016/j.ejmech.2018.11.049>
- Sharma, P., & Gupta, R. (2021). Advancements in drug delivery systems for oxazole derivatives: Enhancing bioavailability and target specificity in cancer therapy. *Journal of Controlled Release*, 332, 303-317.
- Zhang, L., & Chen, W. (2018). Structure-activity relationship of oxazole derivatives as anti-cancer agents: Insights into their design and efficacy. *European Journal of Medicinal Chemistry*, 143, 247-258.
- Kim, H. J., & Lee, J. H. (2017). Mechanisms of action of oxazole derivatives in cancer cells: Inhibition of cell proliferation and induction of apoptosis. *Molecular Pharmacology*, 92(4), 430-444.
- Mishra, A., & Kumar, P. (2020). Oxazole derivatives as promising antimicrobial agents: Antibacterial, antifungal, and antiviral activities. *European Journal of Medicinal Chemistry*, 207, 112760.
- Kumar, A., & Singh, S. (2018). Neuroprotective potential of oxazole derivatives: Implications for Alzheimer's and Parkinson's diseases. *Bioorganic & Medicinal Chemistry*, 26(4), 973-982.
- Chiacchio M.A., Lanza G., Chiacchio U., Giofre S.V., Romeo R., Iannazzo D., Legnani L. Oxazole based compounds as anti-cancer agents. *Curr.Med.Chem.* 2019;26:73377371. doi: 10.2174/0929867326666181203130402.
- Cantalejo YM, Saez B, Monterde MI, Murillo MT, Brana MF (2011) Synthesis and biological activity of new bis pyridinium salts 4,4-bispyridyl, 5-5-perfluoroalkyl 2,2-bisoxazoles. *Eur J Med. Chem.* 46:5662-5667.
- Johan D.O., et al. Discovery of a potent and selective aurora kinase inhibitor, *Bioorg. Med. Chem. Lett.*: 2008. p. 4880-4884. DOI: 10.1016/j.bmcl.2008.07.073.4.
- Liu XH, LV PC, Xue JY, Song BA, Zhu HL (2009) Novel 2,4,5-trisubstituted oxazole derivatives: synthesis and antiproliferative activity. *Eur J Med. Chem.* 44(10):3930-3935.

14. Vladimir Zyabrev, Stepan Pilyo, Bohdan Demydchuk, Maryna Kachaeva, Ivan Semenyuta, Victor Zhirnov, Yevheniia Velihina, Volodymyr Brovarets, ChemMedChem.
15. Barca A, Pani B, Tamaro M, Russo E (1999) Molecular interactions of ruthenium complexes in isolated mammalian nuclei and cytotoxicity on V-79 cells in culture. *Mutat Res* 423(12)171-181
16. Rao, S. S., & Jayaprakash, K. (2018). "Recent developments in oxazole derivatives as potential anticancer agents." *Medicinal Chemistry Research*, 27(2), 431-445.
17. Zhang, H., et al. (2021). "Oxazole-based compounds as promising anticancer agents: A review." *Anti-Cancer Agents in Medicinal Chemistry*, 21(1), 22-40.
18. Chakraborti, A. K., et al. (2020). "Synthesis and biological evaluation of oxazole derivatives as anticancer agents." *Bioorganic & Medicinal Chemistry Letters*, 30(6), 126926.
19. Arora, R., & Gupta, R. (2019). "Emerging roles of oxazole derivatives in cancer therapeutics." *Current Medicinal Chemistry*, 26(34), 6138-6155.
20. Kumar, P., & Singh, R. (2016). "Oxazole derivatives: An overview of their synthesis and biological activities." *European Journal of Medicinal Chemistry*, 112, 236-250.
21. Ghosh, A., et al. (2017). "Oxazole derivatives: A promising class of anticancer agents." *Pharmacological Reports*, 69(5), 978984.
22. Bhagat, D. S., Bumbrah, G. S., Chawla, P. A., Gurnule, W. B., & Shejul, S. K. (2022). Recent Advances in Synthesis and Anticancer Potential of Triazole-Containing Scaffolds. *Anti-Cancer Agents in Medicinal Chemistry*, 22(16).
<https://doi.org/10.2174/1871520622666220217161346>
23. Golani, P., Shah, S. K., & Tyagi, C. K. (2020). Design, synthesis and molecular docking of phenyl [3-(1, 3-oxazol-5-yl) phenyl] carbamate derivatives as novel class of aromatase inhibitors in treatment of breast cancer. *International Journal of Pharmaceutical Research*, 12.
<https://doi.org/10.31838/ijpr/2020.SP1.286>